GSK's Jemperli Recommended for Expanded Approval in Endometrial Cancer, Receives Breakthrough Therapy Designation for Rectal Cancer

MT Newswires Live12-16

GSK (GSK) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanding the approval of its experimental drug, Jemperli, in combination with chemotherapy, as a first-line treatment for adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy.

The company said the recommendation follows positive results from a phase III trial, which showed significant benefits in progression-free and overall survival with the combination treatment.

The final approval decision from the European Commission is expected in Q1 2025, the company said .

Separately, GSK said the US Food and Drug Administration granted Breakthrough Therapy Designation for Jemperli to treat patients with locally advanced, mismatch repair deficient instability-high rectal cancer.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment